202 related articles for article (PubMed ID: 27190350)
21. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.
Pérez-Ruixo JJ; Cucala-Ramos M; García-Gonzalo E; Del Val Romero B; Valveny N
Br J Clin Pharmacol; 2013 Jan; 75(1):15-25. PubMed ID: 22803621
[TBL] [Abstract][Full Text] [Related]
22. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
[TBL] [Abstract][Full Text] [Related]
23. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
[TBL] [Abstract][Full Text] [Related]
24. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
[TBL] [Abstract][Full Text] [Related]
25. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
[TBL] [Abstract][Full Text] [Related]
26. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
27. Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study).
Gesualdo L; Combe C; Covic A; Dellanna F; Goldsmith D; London G; Mann JF; Zaoui P; Turner M; Muenzberg M; MacDonald K; Abraham I
Int Urol Nephrol; 2015 May; 47(5):837-45. PubMed ID: 25894959
[TBL] [Abstract][Full Text] [Related]
28. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013.
Evans M; Suttorp MM; Bellocco R; Hoekstra T; Qureshi AR; Dekker FW; Carrero JJ
Nephrol Dial Transplant; 2016 Apr; 31(4):628-35. PubMed ID: 26243782
[TBL] [Abstract][Full Text] [Related]
29. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease.
Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S
Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003
[TBL] [Abstract][Full Text] [Related]
30. The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients.
Yahiro M; Kuragano T; Kida A; Kitamura R; Furuta M; Hasuike Y; Otaki Y; Nonoguchi H; Nakanishi T
Clin Exp Nephrol; 2012 Jun; 16(3):448-55. PubMed ID: 22270185
[TBL] [Abstract][Full Text] [Related]
31. Fluctuations of haemoglobinaemia in chronic haemodialysis patients.
De Meester J; Maes B; De Vriese A; De Moor B; Donck J; Helbert M; Bammens B; Jamar S
Acta Clin Belg; 2011; 66(2):123-8. PubMed ID: 21630609
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy of a team-led treatment protocol for the management of renal anaemia.
Kotwal SS; Lan P; MacLeod A; Jardine M; Snelling P; Craig J; Cass A; Gallagher M
Nephrology (Carlton); 2013 Oct; 18(10):649-54. PubMed ID: 23889845
[TBL] [Abstract][Full Text] [Related]
33. Management of anaemia in haemodialysis and peritoneal dialysis patients (chapter 8).
Richardson D; Hodsman A; van Schalkwyk D; Tomson C; Warwick G
Nephrol Dial Transplant; 2007 Aug; 22 Suppl 7():vii78-104. PubMed ID: 17724054
[TBL] [Abstract][Full Text] [Related]
34. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
35. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
36. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and predictors of the sub-target Hb level in children on dialysis.
van Stralen KJ; Krischock L; Schaefer F; Verrina E; Groothoff JW; Evans J; Heaf J; Ivanov D; Kostic M; Maringhini S; Podracká L; Printza N; Pundziene B; Reusz GS; Vondrak K; Jager KJ; Tizard EJ;
Nephrol Dial Transplant; 2012 Oct; 27(10):3950-7. PubMed ID: 22740719
[TBL] [Abstract][Full Text] [Related]
38. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
[TBL] [Abstract][Full Text] [Related]
39. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
40. TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients.
Gaweda AE; Bhat P; Maglinte GA; Chang CL; Hill J; Park GS; Ashfaq A; Gitlin M
Hemodial Int; 2014 Jan; 18(1):38-46. PubMed ID: 23968235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
